Early Initiation of Biologics and Disease Outcomes in Adults and Children with Inflammatory Bowel Diseases: Results from the Epidemiology Group of the Nationwide Israeli Inflammatory Bowel Disease Research Nucleus Cohort.

BACKGROUND & AIMS: In this nationwide study, we explored whether early initiation of biologics is associated with improved outcomes in children and adults with Crohn ' s disease (CD) and ulcerative colitis (UC). METHODS: All patients diagnosed with CD or UC in Israel (2005 - 2020) were included in the Epidemiology Group of the Israeli In fl ammatory Bowel Disease Research Nucleus cohort, encompassing 98% of the population. We compared disease duration at biologics initiation (ie, 0 - 3 months, > 3 - 12 months, > 1 - 2 years, and > 2 - 3 years) using the cloning, censoring, and weighting by inverse probabilities method to emulate a target trial, adjusting for time-varying confounders and selection bias. RESULTS: Of the 34,375 included patients (of whom 5240 [15%] were children), 7452 of 19,264 (39%) with CD and 2235 of 15,111 (15%) with UC received biologics. In CD, by 10 years postdiagnosis, the probability of CD-related surgery decreased gradually but modestly with earlier initiation of biologics; a signi fi cant difference was noted between > 2 - 3 years (31%) and 0 - 3 months (18%; P 1 / 4 .02; number needed to treat, 7.7), whereas there was no difference between the 0 - 3-month and > 3 - 12-month periods. The 10-year probability of steroid dependency for the 0 - 3-month period (19%) differed both from the > 2 - 3-year (31%; P < .001) and 1 - 2-year periods (37%; P < .001). In UC, no signi fi cant differences in colectomy or steroid dependency rates were observed between the treatment initiation periods. Similar trends were noted in the pediatric population. CONCLUSIONS: Very early initiation of biologics was not associated with some outcomes except for a modest risk reduction of surgery and steroid dependency for CD, which requires con fi rmation in future studies. In UC, early introduction of biologics was not associated with reduced risk of colectomy or steroid dependency.